Welcome to our dedicated page for Scisparc SEC filings (Ticker: SPRC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SciSparc Ltd. (Nasdaq: SPRC) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer. SciSparc files annual reports on Form 20-F and frequent current reports on Form 6-K, which together describe its clinical-stage pharmaceutical activities, capital structure, and material corporate events.
Recent Form 6-K filings highlight several categories of information. Transaction-related 6-Ks describe agreements such as the asset and share purchase arrangement through which SciSparc obtained a controlling interest in NeuroThera Labs Inc. and transferred its advanced clinical-stage pharmaceutical portfolio and its stake in SciSparc Nutraceuticals Inc. to NeuroThera. Other 6-Ks detail the sale of MitoCareX Bio Ltd. to N2OFF, Inc., the binding term sheet and definitive agreement to acquire a treasury of patents and trademarks for the MUSE endoscopic system from Xylo Technologies Ltd., and a framework agreement terminating a prior merger agreement with AutoMax Motors Ltd. and setting loan repayment terms.
Filings also cover capital markets and compliance matters, including inducement letter agreements with holders of existing warrants, under which warrant exercise prices were adjusted and SciSparc expects to receive gross proceeds for working capital and general corporate purposes. Another 6-K reports a Nasdaq notification that the company no longer met the minimum stockholders’ equity requirement for continued listing, and outlines the timeframe to submit a compliance plan.
In addition, SciSparc uses Form 6-K to furnish financial statements and MD&A, such as unaudited consolidated interim financial statements and management’s discussion and analysis for the six months ended June 30, 2025. Patent- and R&D-related press releases—covering NeuroThera’s opioid–N-acylethanolamine patent, MEAI-based depression patent applications, and the quantum computing-enabled 3D protein modeling initiative—are also incorporated by reference via 6-K exhibits.
On this page, users can review SciSparc’s 6-K submissions, including exhibits like binding term sheets, asset and share purchase agreements, and inducement letters, alongside its 20-F annual report. AI-powered tools summarize key points from these filings, highlight items such as equity transactions, IP acquisitions, and listing status updates, and help readers navigate complex transaction terms and risk disclosures without reading every page in detail.
SciSparc announced that shareholders approved all proposals at their adjourned annual general meeting held on June 26, 2025. The meeting resulted in the approval of two significant documents:
- A new amended and restated articles of association
- An updated compensation policy for executive officers and directors
These approvals were obtained with the requisite majority in accordance with Israeli Companies Law and the company's existing articles of association. The proposals were previously detailed in a proxy statement furnished to the SEC on May 21, 2025.
The Form 6-K filing will be incorporated into multiple company registration statements, including several Form F-3s (File Nos. 333-286099, 333-275305, 333-269839, 333-266047, 333-248670, 333-255408) and Form S-8s (File Nos. 333-278437, 333-225773, 333-286791). The document was signed by Oz Adler, Chief Executive Officer.
SciSparc has filed an amended F-4 registration statement regarding its proposed merger with AutoMax Motors. The merger agreement, initially signed on April 10, 2024, and amended multiple times through May 8, 2025, will result in AutoMax becoming a wholly-owned subsidiary of SciSparc.
Key terms of the merger include:
- AutoMax shareholders and advisor will own approximately 49.99% of SciSparc's share capital post-merger
- SciSparc shareholders will retain approximately 50.01% ownership
- SciSparc will maintain its Nasdaq listing under symbol "SPRC"
- Expected closing in Q3 2025, subject to shareholder and court approvals
A special shareholder meeting is scheduled for August 13, 2025 to vote on: merger approval, new indemnification agreements for directors/officers, executive bonuses contingent on merger closing, and election of new board members. Post-merger, Oz Adler will serve as CEO/CFO, with Dr. Adi Zuloff-Shani as CTO.
SciSparc announced the adjournment of its Annual General Meeting of Shareholders due to lack of quorum on June 25, 2025. The Adjourned Annual Meeting is rescheduled for June 26, 2025, at 8:00 a.m. (Eastern Time) / 3:00 p.m. (Israel time) at the company's Tel Aviv offices.
Key details:
- If quorum is not achieved within 30 minutes of the rescheduled meeting, any number of shareholders present in person, by proxy, or who delivered a proxy card will constitute a quorum
- Previously submitted proxy cards for the original meeting will remain valid for the Adjourned Meeting
- The Form 6-K will be incorporated into multiple registration statements, including Form F-3 and Form S-8 filings
The report was signed by Oz Adler, Chief Executive Officer, on June 25, 2025.
SciSparc Ltd has announced a significant corporate action with a 1-for-21 reverse share split as reported in their Form 6-K filing dated June 28, 2025. This strategic move will consolidate every 21 existing shares into 1 new share.
Key filing details:
- Filing incorporates by reference into multiple registration statements, including Form F-3 (6 filings) and Form S-8 (3 filings)
- Document signed by Oz Adler, who serves as both Chief Executive Officer and Chief Financial Officer
- Company maintains its principal executive offices in Tel Aviv, Israel
- Confirms status as a Form 20-F filer for annual reports
The reverse split announcement suggests a potential strategic effort to meet minimum share price requirements for continued exchange listing or improve the stock's marketability to institutional investors.
SciSparc (Nasdaq: SPRC) filed Amendment No. 2 to its Form F-3 shelf registration, allowing the resale of up to 61,209,538 ordinary shares by existing investors.
The shares consist of (i) 53,617,021 shares issuable upon conversion of $4.2 million in convertible debentures and (ii) 7,592,517 shares issuable upon exercise of warrants. The debenture conversion price equals the lower of a fixed $0.4681 or 95 % of the 20-day VWAP, with a $0.0846 floor; warrants are exercisable at $0.5532. SciSparc will receive no proceeds from share resales, but could receive up to roughly $4.2 million in cash should all warrants be exercised.
The filing reiterates the company’s strategy of developing cannabinoid-based therapeutics (programs SCI-110 and SCI-210) and summarizes its pending merger with AutoMax Motors, an Israeli vehicle importer. The Merger Agreement has been amended four times (latest on 8 May 2025) and remains subject to shareholder approval.
Key investor considerations include: potential dilution from a share count materially larger than current float, a resale overhang that could pressure the $0.321 market price, and ongoing uncertainty surrounding the AutoMax merger. Risk factors highlight limited U.S. enforceability of judgments against the Israeli company and management, and the clinical-stage nature of operations with IFRS-based financials.